Federated Hermes, Inc. Dynavax Technologies Corp Transaction History

Federated Hermes, Inc.

$41.2 Billion
Q2 2024

A detailed history of Federated Hermes, Inc. transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Federated Hermes, Inc. holds 7,146,769 shares of DVAX stock, worth $78.6 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

7,146,769

Previous 7,988,774 10.54%

Holding current value

$78.6 Million

Previous $99.1 Million 19.05%

% of portfolio

0.19%

Previous 0.23%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$10.73 - $12.58 $9.03 Million - $10.6 Million	-842,005 Reduced 10.54%	7,146,769 $80.3 Million
Q1 2024 May 14, 2024	SELL	$11.7 - $14.98 $39.5 Million - $50.6 Million	-3,375,892 Reduced 29.71%	7,988,774 $99.1 Million
Q4 2023 Jan 31, 2024	SELL	$13.09 - $14.98 $16.5 Million - $18.9 Million	-1,264,059 Reduced 10.01%	11,364,666 $159 Million
Q3 2023 Nov 13, 2023	SELL	$12.64 - $14.99 $336,704 - $399,303	-26,638 Reduced 0.21%	12,628,725 $187 Million
Q1 2023 May 08, 2023	BUY	$9.44 - $11.88 $141,600 - $178,200	15,000 Added 0.12%	12,655,363 $124 Million
Q4 2022 Feb 13, 2023	BUY	$10.27 - $13.29 $256,750 - $332,250	25,000 Added 0.2%	12,640,363 $134 Million
Q3 2022 Nov 14, 2022	SELL	$9.93 - $17.44 $33.8 Million - $59.4 Million	-3,407,368 Reduced 21.27%	12,615,363 $132 Million
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $3.84 Million - $6.61 Million	-515,107 Reduced 3.11%	16,022,731 $202 Million
Q1 2022 May 13, 2022	BUY	$9.75 - $14.44 $3.22 Million - $4.77 Million	330,000 Added 2.04%	16,537,838 $179 Million
Q4 2021 Feb 14, 2022	BUY	$13.17 - $20.94 $11.5 Million - $18.3 Million	874,438 Added 5.7%	16,207,838 $228 Million
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $9.98 Million - $21.6 Million	1,089,600 Added 7.65%	15,333,400 $295 Million
Q2 2021 Aug 16, 2021	BUY	$7.25 - $10.99 $11.9 Million - $18 Million	1,639,077 Added 13.0%	14,243,800 $140 Million
Q1 2021 May 13, 2021	BUY	$4.57 - $11.18 $3.01 Million - $7.36 Million	657,923 Added 5.51%	12,604,723 $124 Million
Q4 2020 Feb 12, 2021	BUY	$3.73 - $5.6 $3.73 Million - $5.6 Million	1,000,000 Added 9.14%	11,946,800 $53.2 Million
Q3 2020 Nov 12, 2020	SELL	$4.32 - $11.7 $950,400 - $2.57 Million	-220,000 Reduced 1.97%	10,946,800 $47.3 Million
Q2 2020 Aug 13, 2020	BUY	$2.94 - $9.1 $4.12 Million - $12.7 Million	1,400,000 Added 14.33%	11,166,800 $99.1 Million
Q1 2020 May 13, 2020	BUY	$2.27 - $6.2 $1.18 Million - $3.22 Million	520,000 Added 5.62%	9,766,800 $34.5 Million
Q4 2019 Feb 14, 2020	BUY	$3.46 - $6.93 $1.71 Million - $3.43 Million	495,350 Added 5.66%	9,246,800 $52.9 Million
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $10.5 Million - $19 Million	3,910,750 Added 80.79%	8,751,450 $31.3 Million
Q2 2019 Aug 14, 2019	BUY	$3.65 - $7.89 $3.75 Million - $8.11 Million	1,027,300 Added 26.94%	4,840,700 $19.3 Million
Q1 2019 May 10, 2019	BUY	$7.08 - $12.09 $1.07 Million - $1.84 Million	151,800 Added 4.15%	3,813,400 $27.9 Million
Q4 2018 Feb 13, 2019	BUY	$8.14 - $13.28 $16.8 Million - $27.4 Million	2,062,348 Added 128.96%	3,661,600 $33.5 Million
Q3 2018 Nov 13, 2018	SELL	$11.85 - $16.0 $693,497 - $936,368	-58,523 Reduced 3.53%	1,599,252 $19.8 Million
Q2 2018 Aug 10, 2018	SELL	$15.15 - $20.75 $11.6 Million - $15.9 Million	-764,654 Reduced 31.57%	1,657,775 $25.3 Million
Q1 2018 May 09, 2018	SELL	$14.65 - $19.9 $645,171 - $876,376	-44,039 Reduced 1.79%	2,422,429 $48.1 Million
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $1.75 Million - $2.44 Million	-101,292 Reduced 3.94%	2,466,468 $0
Q3 2017 Nov 13, 2017	BUY	$15.2 - $21.5 $39 Million - $55.2 Million	2,567,760	2,567,760 $55.2 Million

Others Institutions Holding DVAX

# of Institutions

259

Shares Held

132M

Call Options Held

371K

Put Options Held

99.2K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.39B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Dynavax Technologies Corp Transaction History